Anas M. Fathallah, Ph.D.

Co-founder and CEO
LAPIX Therapeutics Inc.

Poster(s):

• (T1030-01-03) Tolerization with a Novel Tim Agonist Dual-Acting Liposomal Formulation Prepares the Immune System for the Success of Gene Therapy
  Tuesday, April 25, 2023

  10:30 AM – 11:30 AM ET

• (M1130-01-04) XenoImmune™ Mouse Model, a Novel and Proprietary Animal Model that Recapitulates Clinical Immunogenicity Rates of Biologics
  Monday, April 24, 2023

  11:30 AM – 12:30 PM ET